A Single-center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biomarker Characteristics of a Single Subcutaneous Injection of GenSci161 Injection in Healthy Adult Participants
Latest Information Update: 23 Mar 2026
At a glance
- Drugs GenSci 161 (Primary)
- Indications Endometriosis; Hidradenitis suppurativa
- Focus Adverse reactions
- Sponsors GeneScience Pharmaceuticals
Most Recent Events
- 23 Mar 2026 New trial record